Table 6.

Positive, negative syndrome, and general psychopathology scales of patients with paranoid schizophrenia receiving haloperidol or risperidone across 12-week study period

Variables	Schizophrenic subjects (n=42)
	SNKc (n=21)						SKc (n=21)
	SNKch (10 mg/day) (n=10)			SNKcr (5 mg/day) (n=11)			SKch (10 mg/day) (n=10)			SKcr (5 mg/day) (n=11)
	Baseline	Week 6	Week 12	Baseline	Week 6	Week 12	Baseline	Week 6	Week 12	Baseline	Week 6	Week 12
Positive (P) (M ± SEM)	27±0.39	25±0.39	24±0.39	28±0.42	25±0.23**	23±0.44**	27.6±0.47	26.7±0.3	26±0.29	29.6±0.33	27.7±0.4	27.2±0.35
Negative (N) (M ± SEM)	29.5±0.34	27.2±0.29**	24.9±0.99**	29±0.43	27±0.44**	24±0.44**	29.9±0.37	28.9±0.48	29.1±0.43	31.18±0.44	30.9±0.31	29.6±0.41
General psychopathology (G) (M ± SEM)	60.3±0.36	55.8±0.38**	51.8±0.38**	60.9±0.43	56±0.35**	50.8±0.32**	61.5±0.37	60.2±0.44**	58±0.42**	59.7±0.42	57±0.31**	54.9±0.25**

Notes: Each value represents as mean ± SEM.

^*For comparison between subjects within each group at 6 weeks or 12 weeks of treatment and baseline.

^**P<0.05.

Abbreviations: S, schizophrenic; K, khat; c, chewing; N, non; r, risperidone; h, haloperidol; SEM, standard error of the mean; M, mean.